CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
CG Oncology To Present Final Results From Phase 2 CORE-001 Study Of Cretostimogene Grenadenorepvec In Combination With Pembrolizumab In BCG-Unresponsive High-Risk NMIBC At ASCO 2024 Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.